Payment overview · 2025
General Payments
$2,654.88
143 reported records · 28 companies
Healthcare provider profile · identity verified
Joseph Hashem, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BERKELEY SPRINGS, WV · NPI 1104859883
Verified facts
What the public records show
CMS Open Payments records show Joseph Hashem, MD received $2,654.88 in general payments during 2025 across 143 reported records.
Amgen Inc. accounted for 10.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Voquezna, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Eliquis by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Voquezna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $282.28 | 10.6% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $263.58 | 9.9% | 13 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $221.99 | 8.4% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $205.01 | 7.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.29 | 7.6% | 16 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $176.84 | 6.7% | 10 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $152.15 | 5.7% | 9 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $127.81 | 4.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.70 | 4.2% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $111.30 | 4.2% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $109.03 | 4.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $91.63 | 3.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.64 | 3.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.77 | 2.6% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $54.13 | 2.0% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.43 | 2.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $51.73 | 1.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.69 | 1.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.50 | 1.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $33.66 | 1.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.52 | 1.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.99 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.96 | 0.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.28 | 0.7% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.48 | 0.6% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $16.33 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.35 | 0.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $13.81 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,634.66 | 142 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $263.58 | 13 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $221.99 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $203.64 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $194.77 | 11 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $176.84 | 10 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $152.15 | 9 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $127.81 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.70 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.70 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $111.30 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $109.03 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $108.57 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $102.46 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.72 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $74.25 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.48 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.77 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.00 | 3 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $59.16 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.56 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.90 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $52.43 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $51.73 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $47.69 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.50 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.47 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $28.52 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $8.86 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 264 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 85 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 172 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 40 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 140 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 166 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
172 | 43 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
264 | 72 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
166 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
172 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
140 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
264 | 72 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 826 | 228 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 539 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 466 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 455 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 421 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 361 | 116 |
| Furosemide | Furosemide | 339 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 321 | 96 |
| Omeprazole | Omeprazole | 314 | 94 |
| Metformin Hcl | Metformin Hcl | 276 | 82 |
| Eliquis | Apixaban | 264 | 72 |
| Quetiapine Fumarate | Quetiapine Fumarate | 256 | 50 |
| Potassium Chloride | Potassium Chloride | 252 | 82 |
| Gabapentin | Gabapentin | 228 | 62 |
| Meloxicam | Meloxicam | 228 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 214 | 61 |
| Alprazolam | Alprazolam | 210 | 38 |
| Allopurinol | Allopurinol | 208 | 62 |
| Losartan Potassium | Losartan Potassium | 200 | 63 |
| Azithromycin | Azithromycin | 197 | 139 |
| Spironolactone | Spironolactone | 195 | 61 |
| Celecoxib | Celecoxib | 194 | 57 |
| Lisinopril | Lisinopril | 193 | 63 |
| Prednisone | Prednisone | 192 | 102 |
| Carvedilol | Carvedilol | 184 | 56 |
| Ezetimibe | Ezetimibe | 183 | 53 |
| Tramadol Hcl | Tramadol Hcl | 183 | 63 |
| Jardiance | Empagliflozin | 172 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 39 |
| Ozempic | Semaglutide | 169 | 39 |
| Sertraline Hcl | Sertraline Hcl | 169 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 166 | 40 |
| Trazodone Hcl | Trazodone Hcl | 161 | 41 |
| Xarelto | Rivaroxaban | 159 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 51 |
| Methylprednisolone | Methylprednisolone | 152 | 127 |
| Simvastatin | Simvastatin | 152 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 48 |
| Lorazepam | Lorazepam | 147 | 36 |
| Glimepiride | Glimepiride | 141 | 47 |
| Mounjaro | Tirzepatide | 140 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 36 |
| Finasteride | Finasteride | 128 | 38 |
| Alendronate Sodium | Alendronate Sodium | 123 | 38 |
| Montelukast Sodium | Montelukast Sodium | 116 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 116 | 31 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 103 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 101 | 80 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 27 |
| Donepezil Hcl | Donepezil Hcl | 91 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 27 |
| Buspirone Hcl | Buspirone Hcl | 89 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 88 | 19 |
| Farxiga | Dapagliflozin Propanediol | 85 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 39 |
| Diazepam | Diazepam | 81 | 16 |
| Pregabalin | Pregabalin | 80 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 31 |
| Synthroid | Levothyroxine Sodium | 74 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 17 |
| Invokana | Canagliflozin | 72 | suppressed |
| Clonazepam | Clonazepam | 70 | 14 |
| Atenolol | Atenolol | 66 | 21 |
| Irbesartan | Irbesartan | 66 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 43 |
| Famotidine | Famotidine | 64 | 24 |
| Midodrine Hcl | Midodrine Hcl | 63 | 14 |
| Sucralfate | Sucralfate | 63 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 62 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 23 |
| Ondansetron Odt | Ondansetron | 62 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 60 | 16 |
| Ibuprofen | Ibuprofen | 59 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | 11 |
| Temazepam | Temazepam | 58 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 47 |
| Chlorthalidone | Chlorthalidone | 56 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 56 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 16 |
| Dexamethasone | Dexamethasone | 54 | 29 |
| Metolazone | Metolazone | 54 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 39 |
| Estradiol | Estradiol | 51 | 17 |
| Nitroglycerin | Nitroglycerin | 51 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 26 |
| Cefuroxime | Cefuroxime Axetil | 49 | 36 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | 18 |
| Digoxin | Digoxin | 47 | 12 |
| Fluconazole | Fluconazole | 47 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 12 |
| Cephalexin | Cephalexin | 46 | 39 |
| Clonidine Hcl | Clonidine Hcl | 46 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 15 |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 46 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 46 | 16 |
| Meclizine Hcl | Meclizine Hcl | 45 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Amoxicillin | Amoxicillin | 44 | 34 |
| Bupropion Xl | Bupropion Hcl | 44 | 17 |
| Repatha Sureclick | Evolocumab | 44 | 13 |
| Torsemide | Torsemide | 43 | 17 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 43 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | 16 |
| Myrbetriq | Mirabegron | 41 | 11 |
| Nadolol | Nadolol | 41 | 16 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 40 | suppressed |
| Kerendia | Finerenone | 40 | 12 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 39 | 18 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 39 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 38 | 16 |
| Rybelsus | Semaglutide | 38 | 11 |
| Methotrexate | Methotrexate Sodium | 37 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | 12 |
| Buprenorphine | Buprenorphine | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 16 |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Primidone | Primidone | 35 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Metronidazole | Metronidazole | 33 | 23 |
| Tadalafil | Tadalafil | 33 | suppressed |
| Scopolamine | Scopolamine | 32 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Voquezna | Vonoprazan Fumarate | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Modafinil | Modafinil | 28 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 15 |
| Humira(Cf) Pen | Adalimumab | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Eplerenone | Eplerenone | 23 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 23 | suppressed |
| Praluent Pen | Alirocumab | 23 | suppressed |
| Sulfasalazine | Sulfasalazine | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Nateglinide | Nateglinide | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cefadroxil | Cefadroxil | 17 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 17 | suppressed |
| Savella | Milnacipran Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
| Rezvoglar Kwikpen | Insulin Glargine-Aglr | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,654.88 · 143 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, Belbuca, CAMZYOS, CAPLYTA, COMIRNATY, ELIQUIS, ENBREL, FARXIGA, FASENRA, FREESTYLE LIBRE 3, JARDIANCE, JOURNAVX, KRYSTEXXA, Kerendia, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, RELISTOR, REPATHA, Rybelsus, TEZSPIRE, TRELEGY ELLIPTA, TWIIST, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error